Odyssey Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|
Revenue | $0 | $1,918 | $1,755 |
EBITDA | -37,018 | ||
EBIT | -38,189 | ||
Net Income | -38,262 | -38,435 | -35,932 |
Net Change In Cash | 0 | 1,918 | 1,755 |
Free Cash Flow | -41,183 | -39,548 | -34,553 |
Cash | 35,719 | 59,136 | |
Basic Shares | 47,174 | 47,174 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,976 | $4,472 | $1,037 | $0 |
Gross Profit | 2,976 | |||
EBITDA | -144,646 | |||
EBIT | -149,557 | |||
Net Income | -148,647 | -129,321 | -125,938 | -124,665 |
Net Change In Cash | 2,976 | 4,472 | 1,037 | 0 |
Free Cash Flow | -130,700 | -118,235 | -117,784 | -112,869 |
Cash | 41,687 | 59,136 | 52,545 | 241,043 |
Basic Shares | 27,561 | 47,174 | 47,174 | 47,174 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$6.74 |